Rallybio Sets Estimated $82.7 Million Special Cash Payout Tied to Merger

what happened

Rallybio has put a provisional figure on a special cash payout to shareholders: roughly $82.7 million, or about $13.56 per share. The payout is connected to the company's planned merger with Avenzo Therapeutics. According to TradingView, which summarized an SEC filing, the amount is derived from net cash above zero under the merger agreement, so the final sum could end up higher or lower than the estimate.

Payment is slated for November 13, 2026, going to eligible common holders and pre-funded warrant holders, and it depends on a stockholder vote. The record date is expected on November 5. Nasdaq is anticipated to make November 6 the ex-dividend date, with due bills expected for trades from November 4 through 6. Separately, the company set the close of business on that same record date for a contingent value rights distribution it announced earlier.

why it matters

For markets this is mainly a corporate event at a small biotech tied to a merger transaction. Investors will watch the timing of the shareholder vote and the final payout figure, which is still an estimate. The ex-dividend date and due bills determine who receives the payment for trades around the event.

market impact

Rallybio shares: the estimated payout and ex-dividend dates shape trading around the Avenzo merger.

tags

instruments